Reports Q3 revenue $266,000, consensus $6.52M. "Based on the encouraging data we reported today from our OASIS study, we are now positioned to advance our suprachoroidal CLS-AX program into a larger randomized, controlled Phase 2 trial," said George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer. "We see significant opportunity across the retinal disease spectrum for CLS-AX, which combines pan-VEGF inhibition from the highly potent tyrosine kinase inhibitor, axitinib, with targeted SCS delivery using our SCS Microinjector. In addition, the growing level of awareness and acceptance of SCS delivery in the retinal medical community is further validating our SCS delivery platform, with recent positive clinical data presented from four other suprachoroidal trials of three different novel therapies each delivered with our proprietary SCS Microinjector."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLSD:
- Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
- Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
- Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
- Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
